Literature DB >> 16953187

Opposite diastereoselective activation of P2Y1 and P2Y11 nucleotide receptors by adenosine 5'-O-(alpha-boranotriphosphate) analogues.

D Ecke1, M E Tulapurkar, V Nahum, B Fischer, G Reiser.   

Abstract

BACKGROUND AND
PURPOSE: We explored the stereoselective activation of the P2Y11 receptor, stably expressed and tagged with GFP, in 1321N1 cells, in comparison to its closest homologue, the P2Y1 receptor. EXPERIMENTAL APPROACH: The potency of several chiral ATP analogues was determined by measuring increases in intracellular calcium concentration ([Ca2+]i). In a series of ATP-alpha-B and ATP-alpha-S analogues, a non-bridging oxygen atom of Palpha was substituted by BH3 or sulphur, respectively, introducing a chiral center at Palpha. The pairs of diastereoisomers (A and B isomers) were each applied as purified compounds. KEY
RESULTS: The (B) isomers (ATP-alpha-B Sp isomers and ATP-alpha-S Rp isomers) of all derivatives tested were more potent at the P2Y11 receptor than the corresponding (A) isomers (ATP-alpha-B Rp isomers and ATP-alpha-S Sp isomers) and the parent compounds. This characteristic of the P2Y11 receptor is opposite to the behaviour of the same diastereoisomers at the P2Y1 receptor, at which the (A) isomers are more active. CONCLUSIONS AND IMPLICATIONS: The distinctly opposite diastereoselective activity of ATP derivatives at the P2Y11 and the P2Y1 receptor will allow the deciphering of structural differences of the ligand recognition sites between these receptor subtypes and may aid in the development of subtype-selective agonists. Moreover, ATP-alpha-B diastereoisomers are not active at the P2Y2 receptor. Thus, they are compounds suitable for distinguishing the functional contribution of the two ATP-activated P2Y receptors, the P2Y2 and P2Y11 receptor, in physiological or pathophysiological responses of cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953187      PMCID: PMC1978435          DOI: 10.1038/sj.bjp.0706887

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells.

Authors:  F Wilkin; X Duhant; C Bruyns; N Suarez-Huerta; J M Boeynaems; B Robaye
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

2.  Adenosine 5'-O-(1-boranotriphosphate) derivatives as novel P2Y(1) receptor agonists.

Authors:  Victoria Nahum; Gregor Zündorf; Sébastien A Lévesque; Adrien R Beaudoin; Georg Reiser; Bilha Fischer
Journal:  J Med Chem       Date:  2002-11-21       Impact factor: 7.446

3.  Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors.

Authors:  Hak Sung Kim; R Gnana Ravi; Victor E Marquez; Savitri Maddileti; Anna-Karin Wihlborg; David Erlinge; Malin Malmsjö; José L Boyer; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2002-01-03       Impact factor: 7.446

4.  Pharmacological characterization of the human P2Y11 receptor.

Authors:  D Communi; B Robaye; J M Boeynaems
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

5.  Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Andrei A Ivanov; Susanna Tchilibon; Pedro Besada; Zhan-Guo Gao; Savitri Maddileti; T Kendall Harden
Journal:  Biochem Pharmacol       Date:  2005-12-15       Impact factor: 5.858

6.  Molecular recognition in purinergic receptors. 1. A comprehensive computational study of the h-P2Y1-receptor.

Authors:  Dan T Major; Bilha Fischer
Journal:  J Med Chem       Date:  2004-08-26       Impact factor: 7.446

7.  Molecular recognition in purinergic receptors. 2. Diastereoselectivity of the h-P2Y1-receptor.

Authors:  Dan T Major; Victoria Nahum; Yingfei Wang; Georg Reiser; Bilha Fischer
Journal:  J Med Chem       Date:  2004-08-26       Impact factor: 7.446

8.  Subtype specific internalization of P2Y1 and P2Y2 receptors induced by novel adenosine 5'-O-(1-boranotriphosphate) derivatives.

Authors:  M E Tulapurkar; W Laubinger; V Nahum; B Fischer; G Reiser
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

9.  Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling.

Authors:  Pamela J White; Tania E Webb; Michael R Boarder
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

10.  Mechanisms of P2X7 receptor-mediated ERK1/2 phosphorylation in human astrocytoma cells.

Authors:  Fernand-Pierre Gendron; Joseph T Neary; Patty M Theiss; Grace Y Sun; Fernando A Gonzalez; Gary A Weisman
Journal:  Am J Physiol Cell Physiol       Date:  2003-02       Impact factor: 4.249

View more
  8 in total

Review 1.  A critical look at the function of the P2Y11 receptor.

Authors:  Karin Dreisig; Birgitte Rahbek Kornum
Journal:  Purinergic Signal       Date:  2016-05-31       Impact factor: 3.765

2.  Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(α or γ)-thio-(α,β- or β,γ)-methylenetriphosphate scaffold.

Authors:  Yael Nadel; Joanna Lecka; Yocheved Gilad; Gal Ben-David; Daniel Förster; Georg Reiser; Sarah Kenigsberg; Jean Camden; Gary A Weisman; Hanoch Senderowitz; Jean Sévigny; Bilha Fischer
Journal:  J Med Chem       Date:  2014-05-30       Impact factor: 7.446

3.  Structure and ligand-binding site characteristics of the human P2Y11 nucleotide receptor deduced from computational modelling and mutational analysis.

Authors:  Jacques Zylberg; Denise Ecke; Bilha Fischer; Georg Reiser
Journal:  Biochem J       Date:  2007-07-15       Impact factor: 3.857

4.  Diastereoselectivity of the P2Y11 nucleotide receptor: mutational analysis.

Authors:  D Ecke; B Fischer; G Reiser
Journal:  Br J Pharmacol       Date:  2008-09-29       Impact factor: 8.739

5.  Receptor-independent effects of 2'(3')-O-(4-benzoylbenzoyl)ATP triethylammonium salt on cytosolic pH.

Authors:  Juan Pablo Reyes; Matthew W Grol; Stephen M Sims; S Jeffrey Dixon
Journal:  Purinergic Signal       Date:  2013-05-22       Impact factor: 3.765

6.  A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist.

Authors:  Tali Fishman Jacob; Vijay Singh; Mudit Dixit; Tamar Ginsburg-Shmuel; Begoña Fonseca; Jesus Pintor; Moussa B H Youdim; Dan T Major; Orly Weinreb; Bilha Fischer
Journal:  Purinergic Signal       Date:  2018-07-17       Impact factor: 3.765

Review 7.  Update of P2Y receptor pharmacology: IUPHAR Review 27.

Authors:  Kenneth A Jacobson; Esmerilda G Delicado; Christian Gachet; Charles Kennedy; Ivar von Kügelgen; Beibei Li; M Teresa Miras-Portugal; Ivana Novak; Torsten Schöneberg; Raquel Perez-Sen; Doreen Thor; Beili Wu; Zhenlin Yang; Christa E Müller
Journal:  Br J Pharmacol       Date:  2020-04-06       Impact factor: 9.473

8.  Development of selective agonists and antagonists of P2Y receptors.

Authors:  Kenneth A Jacobson; Andrei A Ivanov; Sonia de Castro; T Kendall Harden; Hyojin Ko
Journal:  Purinergic Signal       Date:  2008-07-04       Impact factor: 3.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.